SCHEMBL16665165

SCHEMBL16665165

Nc1ccc(C(=O)NC2CCCC(Nc3ncc(Cl)c(-c4c[nH]c5ccccc45)n3)C2)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ CDK7 P50613 15/20 1.00
▸ CCNT1 O60563 7/20 0.69
▸ CDK9 P50750 7/20 0.69
▸ CCNK O75909 6/20 0.69
▸ CDK12 Q9NYV4 6/20 0.69
▸ CCNH P51946 5/20 0.69
▸ MNAT1 P51948 3/20 0.69
▸ CDK2 P24941 7/20 0.60
▸ CCNE1 P24864 3/20 0.60
▸ CRBN Q96SW2 1/20 0.60
▸ JUN P05412 4/20 0.59
▸ MAPK8 P45983 4/20 0.59
▸ MAPK9 P45984 4/20 0.59
▸ MAPK10 P53779 2/20 0.59
▸ CDK13 Q14004 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22778392 1.00 CDK7 (1.00) CDK7CCNT1CDK9CCNKCDK12
SCHEMBL16665084 1.00 CDK7 (1.00) CDK7CCNT1CDK9CCNKCDK12
SCHEMBL17150574 0.92 CDK7 (0.85) CDK7CCNT1CDK9CCNKCDK12
SCHEMBL20764177 0.92 CDK7 (0.85) CDK7CCNKCDK12CCNHMNAT1
SCHEMBL17150546 0.91 CDK7 (0.84) CDK7CCNT1CDK9CCNKCDK12
SCHEMBL23336215 0.91 CDK7 (0.83) CDK7CCNT1CDK9CCNKCDK12
SCHEMBL17688417 0.90 CDK7 (0.87) CDK7CCNT1CDK9CCNKCDK12
SCHEMBL17150627 0.90 CDK7 (0.82) CDK7CCNT1CDK9CCNKCDK12
SCHEMBL16665088 0.90 CDK7 (0.87) CDK7CCNT1CDK9CCNKCDK12
SCHEMBL17696266 0.90 CDK7 (0.87) CDK7CCNT1CDK9CCNKCDK12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210061803-A1 INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) SYROS PHARMACEUTICALS INC (US) 2021-03-04 — — US disclosed
US-10865206-B2 Inhibitors of cyclin-dependent kinase 7 (CDK7) SYROS PHARMACEUTICALS, INC. (US) 2020-12-15 — — US disclosed
US-20190337940-A1 INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) OXFORD FINANCE LLC, AS COLLATERAL AGENT 2019-11-07 — — US disclosed
US-10308648-B2 Inhibitors of cyclin-dependent kinase 7 (CDK7) SYROS PHARMACEUTICALS, INC. (US) 2019-06-04 — — US disclosed
US-20170327496-A1 INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) OXFORD FINANCE LLC, AS COLLATERAL AGENT 2017-11-16 — — US disclosed
US-20170327496-A1 INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) OXFORD FINANCE LLC, AS COLLATERAL AGENT 2017-11-16 — — US disclosed
WO-2016058544-A1 INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) SYROS PHARMACEUTICALS, INC. (US) 2016-04-21 — — WO disclosed
WO-2015058140-A1 POLYCYCLIC INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) DANA-FARBER CANCER INSTITUTE, INC. (US) 2015-04-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190337940-A1 INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) CDK7, CDK3, CDK9 CDK7 1/4885CCNT1 33/4885CDK9 3/4885
US-10308648-B2 Inhibitors of cyclin-dependent kinase 7 (CDK7) CDK7, CDK3, CDK9 CDK7 1/4885CCNT1 33/4885CDK9 3/4885
US-20170327496-A1 INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) CDK7, CDK3, CDK9 CDK7 1/4885CCNT1 33/4885CDK9 3/4885
US-20210061803-A1 INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) CDK7, CDK3, CDK9 CDK7 1/4885CCNT1 33/4885CDK9 3/4885
US-10865206-B2 Inhibitors of cyclin-dependent kinase 7 (CDK7) CDK7, CDK3, CDK9 CDK7 1/4885CCNT1 33/4885CDK9 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback